Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.62% is 32% above its 5-year average of -46.34%, near the high end of its 5-year range (-59.62%–-31.62%).
24.44% above its 12-month average of -41.85%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.17%.
RETURN ON ASSETS (ROA)
-31.62%
RETURN ON ASSETS (ROA) AVG TTM
-41.85%
RETURN ON ASSETS (ROA) AVG 3Y
-50.05%
RETURN ON ASSETS (ROA) AVG 5Y
-46.34%
RETURN ON ASSETS (ROA) AVG 10Y
-43.39%
RETURN ON ASSETS (ROA) AVG 15Y
-52.92%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.44%
CURRENT VS 3Y AVG
+36.83%
CURRENT VS 5Y AVG
+31.76%
CURRENT VS 10Y AVG
+27.12%
CURRENT VS 15Y AVG
+40.25%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+1.92%
vs the sector median at left
Iovance Biotherapeutics, Inc.
Market Cap
$5.87B
Return on Assets (ROA)
-31.62%
TTM Avg
-41.85%
3Y Avg
-50.05%
5Y Avg
-46.34%
Market Cap
$5.85B
Return on Assets (ROA)
9.00%
TTM Avg
0.15%
3Y Avg
10.71%
5Y Avg
-11.86%
Market Cap
$5.94B
Return on Assets (ROA)
-13.77%
TTM Avg
-40.95%
3Y Avg
-52.61%
5Y Avg
-44.58%
Market Cap
$5.94B
Return on Assets (ROA)
9.02%
TTM Avg
3.77%
3Y Avg
2.45%
5Y Avg
2.33%
Market Cap
$5.95B
Return on Assets (ROA)
-94.23%
TTM Avg
-58.97%
3Y Avg
-55.59%
5Y Avg
-44.06%
Market Cap
$5.63B
Return on Assets (ROA)
-20.67%
TTM Avg
-16.00%
3Y Avg
-20.09%
5Y Avg
-20.45%
Market Cap
$5.52B
Return on Assets (ROA)
-0.50%
TTM Avg
-0.21%
3Y Avg
0.03%
5Y Avg
0.08%
Market Cap
$6.24B
Return on Assets (ROA)
-46.96%
TTM Avg
-53.68%
3Y Avg
-52.55%
5Y Avg
-50.20%
Market Cap
$5.46B
Return on Assets (ROA)
-6.97%
TTM Avg
-6.55%
3Y Avg
-3.96%
5Y Avg
-3.96%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $5.87B | -31.62% | -41.85% | -50.05% | -46.34% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.85B | 9.00% | 0.15% | 10.71% | -11.86% |
| GRAIL Inc. (GRAL)vs › | $5.94B | -13.77% | -40.95% | -52.61% | -44.58% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 9.02% | 3.77% | 2.45% | 2.33% |
| Kodiak Sciences Inc. (KOD)vs › | $5.95B | -94.23% | -58.97% | -55.59% | -44.06% |
| CG Oncology Inc. (CGON)vs › | $5.63B | -20.67% | -16.00% | -20.09% | -20.45% |
| RadNet, Inc. (RDNT)vs › | $5.52B | -0.50% | -0.21% | 0.03% | 0.08% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.24B | -46.96% | -53.68% | -52.55% | -50.20% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.46B | -6.97% | -6.55% | -3.96% | -3.96% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.34B | -1.18% | 1.12% | -15.90% | -18.41% |
ROA
-31.6%
ROE
-39.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -42.82% |
| 2024-12-31 | -40.88% |
| 2023-12-31 | -56.90% |
| 2022-12-31 | -59.62% |
| 2021-12-31 | -44.03% |
| 2020-12-31 | -33.78% |
| 2019-12-31 | -57.32% |
| 2018-12-31 | -25.70% |
| 2017-12-31 | -59.25% |
| 2016-12-31 | -30.77% |
| 2015-12-31 | -26.18% |
| 2014-12-31 | -25.88% |
| 2013-12-31 | -127.71% |
| 2012-12-31 | -11246.73% |
| 2011-12-31 | -4520.17% |
| 2010-12-31 | -110.07% |
| 2009-12-31 | -163.75% |
| 2008-12-31 | -1018.18% |
